Management of relapsed multiple myeloma: A BSH and UK Myeloma Society guideline

Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline

Scope: The objective of this guideline is to provide healthcare professionals with clear guidance on the management of patients with relapsed and refractory multiple myeloma who have disease progression after at least one prior therapy. These guidelines and recommendations do not replace multidisciplinary discussion and the need to take account of clinical features, patient preference and the funding and reimbursement of treatments at any given point in time.

Introduction: This guideline aims to outline the optimal management of patients with relapsed and/or refractory myeloma. It includes recommendations about evaluation and monitoring of patients with relapsed disease and their subsequent treatment. There are many factors that influence choice of treatment at each line of therapy, and therefore, it is not possible or desirable to generate a single algorithm to guide treatment. However, these guidelines aim to reflect the most robust data available at the time of publication. These should complement multidisciplinary discussion, and patient-specific factors must always be taken into consideration. These guidelines focus on the United Kingdom, but include regimens that at the time of publication may not be reimbursed in all regions of the United Kingdom, even though robust evidence for their use exists.


Read full Guideline